PPT-Elbasvir-Grazoprevir

Ribavirin in HCV Genotype 1 4 or 6 CEDGE Treatment Experienced TE Phase 3 Treatment Experienced Kwo P et al EASL 2015 Abstract P0886 Source Kwo P et al EASL 2015 Abstract P0886. Design. C-SCAPE . Study. : . grazoprevir. ± . elbasvir. ± RBV . in . genotypes. 2, 4, 5 or 6. Treatment-naïve . Genotype 2. , 4, 5, 6. Non-cirrhotic, . HCV . monoinfected. Brown . A. . . J . Hepatol. C-WORTHY Study Part C: . grazoprevir. . + . elbasvir. ± RBV in genotype 1b. GZR + EBR + RBV. N = 30. N = 31. Design. W8. C-WORTHY/C. Vierling. . JM. EASL 2015, . Abs. . P0769 . >. 18 years. HCV genotype 1b. Design. C-SCAPE . Study. : . grazoprevir. ± . elbasvir. ± RBV . in . genotypes. 2, 4, 5 or 6. Treatment-naïve . Genotype 2. , 4, 5, 6. Non-cirrhotic, . HCV . monoinfected. Brown . A. . . J . Hepatol. + . Grazoprevir. +/- Ribavirin in . Treatment-Naïve HCV . GT 2, 4, 5, or 6. C-SCAPE. Phase . 2 . Treatment. . Naïve. Brown A, . et al. . EASL 2015; Abstract P0771.. Source: Brown A, et al. EASL 2015; Abstract P0771.. + . Grazoprevir. in . GT 1 . and Chronic Renal Disease. C. -SURFER. Phase 3. Treatment. Naïve and Treatment . Experienced. Roth D, . et al. Lancet . 2015;386:1537-45.. Source: Roth . D, et al. Lancet 2015;386:1537-45.. . + . Sofosbuvir. . in Treatment-Naïve HCV Genotype . 1 or 3. C-SWIFT. Phase . 2 . Treatment. . Naïve. Poordad. . F, . et al. . EASL 2015; Abstract O006.. Source: . Poordad. F, et al. EASL . 2015; Abstract . X. J . Hepatology. 2015; 63: 564-72. C-SALVAGE Study: . grazoprevir. . + . elbasvir. + RBV in genotype 1 with failure to PI-based regimen. NS3 and NS5A RAVs identified by population sequencing at baseline and VF. N = 45. N = 49. W24. W16. MK3. > . 18 years. HCV infection. G. enotype 1. Relapse after LDV/SOF or EBR/GZR. Compensated . cirrhosis** . allowed. Well-controlled HIV co-infection allowed. Randomisation. Randomisation*. Open-label. >. 18 years. HCV genotype 1. HCV RNA ≥ 10,000 IU. /ml. Treatment naïve and . compensated cirrhosis (Child-Pugh A). or. Null responders to previous PEG-IFN + RBV, with or without cirrhosis. in genotypes 1 or 3, with or without cirrhosis. >. 18 years. Chronic HCV infection. Genotype 1 or 3. HCV RNA > 10 000 IU. /ml. Treatment-naïve . Cirrhosis assessed by liver biopsy or noninvasive tests. 6; 386:1537-45. C-SURFER Study: . grazoprevir. . + . elbasvir. . in genotype 1 with chronic kidney disease. N = 111. GZR + EBR. Placebo. GZR + EBR (Intensive PK). N = 113. N = 11. GZR/EBR. W. 12. W16. Ribavirin in PI-experienced HCV GT1. C-SALVAGE. Phase . 2 . Treatment. . Experienced. (1) . Buti. M, et al. . Clin. Infect Dis. 2016;62:32-6. (2) . Forns. X, et al. J . Hepatol. . 2015;63:564-72. C-EDGE Treatment Naïve (TN). Phase 3. . Treatment. . Naïve. Zeuzem. S, . et al. . Ann Intern Med. 2015;163:1-13.. Source: . Zeuzem. S, et al. Ann Intern Med. 2015;163:1-13. .. Elbasvir-Grazoprevir. Medical Director, Austin Hepatitis Center. 1. Hepatitis C & PCP’s. 2. LACK OF AWARENESS. LACK OF APPROPRIATE ACTION. Expand Quantitative Landscape Study – Oct 2013 [Gilead Sciences]. 35-50% of PCP believe HCV can be cured.